Publication | Closed Access

Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

Breast OncologyOncologyAnti-resorptive EffectsMedicinePathologyPaclitaxel InduceBreast CancerAnti-cancer AgentCancer TreatmentPharmacologyCancer GrowthTumor BiologySorafenib Tosylate